Lupin gets USFDA nod for biosimilar drug

Lupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at Lupin’s Pune facility. Armlupeg aims to reduce infection risk from chemotherapy, and Lupin plans to expand its US biosimilar portfolio. The US market for Pegfilgrastim is worth over $1.29 billion annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Tj2Ivca
via IFTTT

Read More

Sun Pharma brings global psoriasis drug ILUMYA to Indian market

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This novel treatment, Tildrakizumab, has a proven track record globally for providing significant and sustained skin clearance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e5Ki80u
via IFTTT

Read More

Lupin Pharma, TPG Capital & EQT in talks to acquire Lalvani family-owned Vitabiotics

Indian drugmaker Lupin and private equity firms are exploring the acquisition of UK's Vitabiotics. The deal is valued at approximately one billion pounds. Several Indian companies had previously considered the acquisition but stepped back due to valuation concerns. Vitabiotics' Indian arm, Meyer Vitabiotics, contributes significantly to its annual sales. The nutraceutical market in India is experiencing rapid growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sNV1AuZ
via IFTTT

Read More

Torrent Pharma fined Rs 41 crore over alleged wrong GST refund

Torrent Pharmaceuticals has been fined Rs 41 crores by the Central GST Ahmedabad South Commissionerate. The company faces allegations of wrongful refund claims on export of goods. Torrent Pharmaceuticals plans to appeal the order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6HOgYLl
via IFTTT

Read More

Apollo Pharmacy targets 10 crore customer base in 5 years, to open 2 new stores per day: CEO

Apollo Pharmacy plans an aggressive expansion, aiming to open two new stores daily to reach a customer base of 10 crore within five years. Having surpassed 7,000 stores, the omni-channel network seeks to enhance its neighbourhood presence and ensure widespread access to quality medicines. The company also reported its loyalty program, Apollo Circle, has crossed 10 million members.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8JLC52k
via IFTTT

Read More

Generic HIV drug rollout to take a hit on trial push

India's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts warn this will delay access to the affordable generic version for millions in India and other low-income nations. Drug maker Hetero Labs sought the waiver to speed up the launch of the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BDUcR9e
via IFTTT

Read More

Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Glenmark Pharmaceuticals has received a positive report from the US health regulator. The company's manufacturing facility in Monroe, North Carolina, has been classified as Voluntary Action Indicated. This development means the facility can now restart commercial manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTzZfPs
via IFTTT

Read More

Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classification

Biocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classification means that while some objectionable conditions were found during the inspection, the agency is not pursuing regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mD6zjSv
via IFTTT

Read More

Kauvery Hospitals' promoters look to buy back 5% stake from Lightrock

Kauvery Hospitals' leadership is engaged in discussions to repurchase shares from the investor Lightrock, with the valuation of the healthcare chain set at ₹5,000 crore. Anticipating a public offering in the next two years, the group is poised to ramp up its bed capacity significantly. The primary goal for the promoters is to reclaim a stronger stake in their enterprise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RuNktyQ
via IFTTT

Read More

Lord’s Mark Industries acquires 85% stake in Renalyx to scale indigenous dialysis technology

Lord's Mark Industries has acquired an 85% stake in Renalyx Health Systems, a Bengaluru-based med-tech firm known for its AI-powered smart hemodialysis machine. This strategic move aims to bolster Lord's Mark's presence in advanced medical technologies, particularly for chronic kidney disease. Renalyx will spearhead R&D for kidney and liver devices, enhancing renal care accessibility across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jNZkagl
via IFTTT

Read More

China holds all the cards in global pharmaceuticals despite India’s bid to reshuffle the deck

China's dominance over raw materials for medicines presents a significant supply-chain vulnerability for the US. A US commission urges Congress to require pharmaceutical firms to report supply chain origins and encourage diversification away from China, highlighting the risks of over-reliance on a geopolitical rival.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K5BSoNt
via IFTTT

Read More

Sterling Biotech case: GoI to examine impact of Supreme Court judgment

The government is reviewing the Supreme Court's Sterling Biotech judgment, which dropped criminal charges against promoters in exchange for a ₹5,100 crore payment. While not a precedent, the ruling raises concerns for lenders and could impact similar fraud cases, potentially encouraging other offenders to seek settlements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InojfUu
via IFTTT

Read More

Baby Memorial Hospital front-runner for Star Hospitals, Fortis also in fray

Baby Memorial Hospital, backed by KKR, is reportedly the front-runner to acquire Star Hospitals for ₹2,500-2,700 crore. Fortis Healthcare is also in contention for the Hyderabad-based hospital group. Star Hospitals, promoted by cardiologist Gopichand Mannam, has two facilities in Hyderabad and annual revenues of ₹500-600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TMkXsQ6
via IFTTT

Read More

Glenmark launches fixed-dose triple therapy for COPD

Glenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three medicines to improve lung function and symptom control. It offers a new standard of care, especially for patients who find inhalers difficult. The therapy showed rapid improvement in lung function and breathlessness in a clinical study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UGXfCxT
via IFTTT

Read More

US FDA approves Novartis' gene therapy for rare muscle disorder

The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma offers a new option for a broader patient group. The therapy aims to replace a faulty gene crucial for muscle function.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WXvlp1M
via IFTTT

Read More

NPPA extends price cap on knee implants by a year

India's drug pricing regulator has extended the price cap on knee implants. This decision will continue to benefit patients by keeping costs down. The National Pharmaceutical Pricing Authority decided not to revise the prices for another year. Manufacturers had argued for a price increase, citing research and development needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HrkSoLW
via IFTTT

Read More

BlackRock exiting Rs 210 crore investment in People Tree Hospitals

People Tree Hospitals is facilitating an exit for BlackRock. BlackRock invested Rs 210 crore earlier this year. This investment aided the hospital chain's expansion and super-speciality services. It marked BlackRock's first major healthcare investment in India. People Tree Hospitals operates several branches across Bengaluru and Karnataka. Founder Jothi Neeraja stated commitment to honoring investor trust.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MsNBnAa
via IFTTT

Read More

Corner Office Conversation: Nandini Piramal of Piramal Pharma & Arjun Juneja of Mankind Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aojdn7U
via IFTTT

Read More

Biocon chief bats for dual-agency model to fast-track drug approvals

Biocon's Kiran Mazumdar-Shaw suggests a new drug approval system. The Indian Council of Medical Research would handle scientific reviews for new drugs and devices. The Central Drugs Standard Control Organisation would then grant final regulatory approval. This aims to speed up innovation and research in India's biotechnology sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bF3Gr5p
via IFTTT

Read More

Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4

Aurobindo Pharma's China facility is set to achieve break-even by the end of fiscal year 2026. The company anticipates significant growth driven by its Pen-G facility ramp-up and biosimilar portfolio commercialization. The US market will see contributions from the Dayton facility starting January. Aurobindo aims for a 20-21 percent margin target for FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HV0z9u1
via IFTTT

Read More

India mulls floating global tenders for key patented drugs amid supply gaps

The government is examining a proposal to float global tenders for more than 65 patented and proprietary medicines — including obesity, cancer, cardiac and diabetes drugs — to supply central healthcare institutions such as the armed forces’ medical wing and the Employees’ State Insurance Corporation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KxmGa58
via IFTTT

Read More

Pharma Industry warns minimum import prices plan could raise drug prices, hurt MSMEs

Pharma experts have flagged concerns over the government’s plan to set minimum import prices (MIP) for key drug ingredients such as Penicillin-G, 6APA and amoxicillin. They warn this will raise manufacturing costs, increase medicine prices and hurt over 10,000 MSMEs, potentially causing major job losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UrBJILh
via IFTTT

Read More

Government’s scheme to promote research and innovation evokes a massive response: Official

A month after the Department of Pharmaceutical (DoP) invited applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, an initiative to transform the sector into a globally competitive, innovation-driven sector, 700 applications have been received by the department so far.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ag4y0pc
via IFTTT

Read More

Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate growth in the biologics space. The company is uniquely positioned with interchangeable biosimilar insulins and aims to capitalize on the growing GLP-1 market, bolstered by its acquisition of Viatris' biosimilars business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtATbsf
via IFTTT

Read More

Quality issues: Regulator looks to tighten marketing & sale of drugs

India's drug regulator plans new rules for medicine marketers. Companies will need a license to sell and distribute drugs. This aims to improve drug quality and safety. The move will impact domestic and multinational firms. It is expected to help curb fake medicines. The regulator seeks to create a database of marketers for better oversight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/64tJVoU
via IFTTT

Read More

Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early momentum for Mounjaro in India, where the dual-action diabetes and obesity drug has clocked ₹450 crore in sales within seven months. He said India has a large unmet need, with nearly 100 million people living with obesity and diabetes, and that tirzepatide’s dual GIP and GLP-1 mechanism has set it apart in both weight and glucose management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vM7qKj1
via IFTTT

Read More

Ultra-processed foods displacing fresh meals worldwide, driving chronic disease burden: Lancet

Ultra-processed foods are increasingly displacing healthier options globally, contributing to chronic diseases. Researchers urge immediate public health action, emphasizing coordinated policies to curb UPF production, marketing, and consumption. This requires challenging corporate influence and advocating for sustainable food systems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wrFt7Tm
via IFTTT

Read More

Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya

Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring its successful insulin strategy. Ozempic is slated for launch within three months, with pricing to be determined by market research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZpOYeD7
via IFTTT

Read More

After cough syrup deaths, drug regulator moves to tighten rules on high-risk solvents; unlicensed village pharmacies also under scrutiny

India's drug regulator is taking action after children died from contaminated cough syrups. They are looking into how to check the quality of ingredients like propylene glycol. The regulator is also considering stopping unlicensed pharmacists from selling cough syrups in villages. Experts are being consulted on whether to replace propylene glycol in these medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6b8A5l3
via IFTTT

Read More

NCLT clears Sequent Scientific–Viyash Life Sciences merger worth ₹8,000 crore

Carlyle's portfolio companies, Sequent Scientific and Viyash Life Sciences, have received National Company Law Tribunal approval for their planned Rs 8,000 crore merger. This strategic combination aims to leverage back-end synergies between Sequent's animal health business and Viyash's human health drug manufacturing operations. Hari Babu Bodepudi, Viyash's founder, will lead the combined entity as CEO.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i0Y3AqC
via IFTTT

Read More

Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India

Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion, and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative therapies. They are working with partners to reach more people across India. This ensures their medicines benefit a wider population.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gjzOyd6
via IFTTT

Read More

Import price floor on cards for critical pharma inputs

India is setting a minimum import price for essential drug ingredients. This move aims to shield local manufacturers from cheap imports, particularly from China. The government is expanding this policy to include more raw materials. This initiative supports India's goal of becoming self-reliant in pharmaceutical production. The new rules will soon be announced.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LpjBwfM
via IFTTT

Read More

Deep Diamond India to enter preventive healthcare segment

The digital-health initiative, Deep Health India AI, is an intelligent, camera-based wellness platform that uses facial-scan technology to deliver real-time health insights, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IbtOxFS
via IFTTT

Read More

Pfizer launches new medication for migraine treatment

In a significant breakthrough for migraine sufferers in India, Pfizer has launched Rimegepant ODT, an innovative oral tablet that dissolves on the tongue. This medication provides rapid pain relief lasting up to 48 hours without the need for water, helping individuals reclaim lost days due to debilitating headaches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oPjyJ34
via IFTTT

Read More

AI tool in national disease surveillance helped issue over 5,000 alerts to health authorities: Data

Nearly 200 countries are legally bound by the International Health Regulations (IHR) to operate a national disease surveillance system. The IHR and World Health Organization work together in protecting global health security. News reports in print, electronic and online media are scanned by media scanning and verification tool under India's 'Integrated Disease Surveillance Programme' (IDSP) for unusual health events, which are then shared with authorities for further action, if deemed necessary.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwfPhjO
via IFTTT

Read More

Wealth Whisperers: Meet wealth psychologists who help the ultra-rich deal with money-related stress

Wealthy individuals, even after achieving financial success, often grapple with profound emotional turmoil like panic, insomnia, and identity loss. A new breed of professionals, wealth psychologists, are emerging to address the emotional meaning of money, helping the affluent navigate issues of guilt, isolation, and purpose beyond material gain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TF4NeJi
via IFTTT

Read More

Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors

India's pharmaceutical industry total market size is projected to reach $130 billion by 2030 and an impressive $450 billion by 2047, highlighting the country's growing role as a global pharmaceutical powerhouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/319b6s5
via IFTTT

Read More

Lupin launches generic injection in US with 180-day exclusivity

In an exciting development for mental health treatment, Lupin has introduced a generic version of a medication for schizophrenia and bipolar disorder in the US. This innovative product comes as an extended-release injectable suspension and is backed by a remarkable 180 days of exclusivity. This launch illustrates Lupin's commitment to advancing complex injectable solutions in a growing US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TxpG8tF
via IFTTT

Read More

Small pharma firms may face closure as regulator tightens quality checks

Many small drug makers face closure as regulators inspect facilities for quality standards. Thousands of plants may shut down if upgrades are not made. This could lead to drug shortages. Industry groups are seeking more time to comply. The government has set a deadline for these upgrades. Companies must submit plans for improvement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pv6ZORL
via IFTTT

Read More

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review

Biocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company is in advanced talks with minority investors for a share swap, considering various value creation options including an IPO or merger. This move aims to address acquisition-related debt and unlock shareholder value.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rdbjDKk
via IFTTT

Read More

Eli Lilly drops CVS drug plan for staff after Novo obesity deal: Report

Eli Lilly is switching its employee drug benefit plan from CVS Health to Rightway, a move reportedly linked to CVS's decision to stop covering Lilly's weight-loss drug Zepbound in favor of Novo Nordisk's Wegovy. Lilly stated the change was due to Rightway offering competitive fees and services aligned with employee interests.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8pKIOvw
via IFTTT

Read More

NTPC inks two pacts in Assam; to build burn ICU at KMCH, support TB patients

In a statement, the country's largest power producer said that it will construct a six-bed Intensive Care Unit (ICU) in the burn unit at Kokrajhar Medical College and Hospital (KMCH). The other project is nutritional support for 200 TB patients under the Pradhan Mantri TB Mukt Bharat Abhiyan in the district.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/173vOC2
via IFTTT

Read More

Lupin unit commissions oncology block at Vizag plant to expand CDMO biz

Drug firm Lupin has commissioned a new oncology block at its Vizag manufacturing plant. This dedicated unit will boost contract development and manufacturing services for high-potent active pharmaceutical ingredients. The facility supports clients throughout the oncology drug development lifecycle. It integrates process development and quality control labs for efficient operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TbUCeEN
via IFTTT

Read More

Emcure Pharma Q2 profit rises 25%, revenue up 13% on broad-based growth

Pune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supported by double-digit growth in both domestic and international markets. Net profit increased 24.7% YoY to ₹251 crore, while EBITDA rose 15.2% to ₹439 crore, with a margin of 19.3%, the company said on Tuesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uUoaJhO
via IFTTT

Read More

Novo, Emcure to launch weight-loss drug under new brand in India

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the company has not yet disclosed pricing details for Poviztra. Wegovy is currently priced between ₹17,345 and ₹26,050 across dosages in India. It is prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TrXuex9
via IFTTT

Read More

Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in India

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand access to the drug by leveraging Emcure's extensive distribution network and field force, addressing a significant need for wider reach beyond current accessibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bcV0lYA
via IFTTT

Read More

Novo Nordisk, Emcure to launch weight-loss drug under new brand in India

Novo Nordisk has partnered with Emcure Pharmaceuticals to bring Poviztra, their latest weight-loss medication, to the Indian market. This collaboration builds on Novo Nordisk's prior success with Wegovy and follows Eli Lilly's competition in this space. After the announcement, Emcure Pharma's stock experienced a notable uptick, signaling investor confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W6fIDRJ
via IFTTT

Read More

Cyber fraud: Dr Reddy's Laboratories loses Rs 2.16 cr after fraudsters hack email communication

Bengaluru police are investigating a Rs 2.16 crore cyber fraud where hackers infiltrated email communications between Group Pharmaceuticals and Dr Reddy's Laboratories. The fraudsters impersonated Group Pharmaceuticals officials, diverting the payment to a fraudulent account in Gujarat. The primary account has been frozen, and efforts are underway to recover the funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PhZ6Ufs
via IFTTT

Read More

Apollo’s Suneeta Reddy and Dr Preetha Reddy on the Next 10 Years of Healthcare

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HEXR6dn
via IFTTT

Read More

Centre asks states to take steps to encourage organ, tissue donation from road accident victims

In India, the challenge of organ shortages looms large. The government is calling on states to amplify efforts in organ donation. Vital steps include training first responders and enhancing hospital trauma centers for effective organ recovery. This initiative specifically targets increasing the number of organ donors from tragic road accident cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2uCrJ7Q
via IFTTT

Read More

Venus Remedies gets new market authorisations for drugs in Vietnam

Pharma major Venus Remedies has received new marketing authorisations in Vietnam for its drugs Methotrexate, Cefuroxime, and Irinotecan. These approvals expand the company's presence in South Asia's growing pharmaceutical market. This marks 29 active product approvals for Venus Remedies in Vietnam alone. The company is committed to increasing access to critical care therapies in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x7skF8H
via IFTTT

Read More

Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle

Metsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per share. Metsera's board recommended shareholders approve the deal. Pfizer aims to strengthen its position in the growing weight-loss drug market. The merger is expected to close soon after Metsera's shareholder meeting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ujIGeUB
via IFTTT

Read More

Drug regulator for strict compliance with new Schedule M

The state drug regulators have been asked to submit monthly reports to the Central Drugs Standard Control Organisation on the inspections and observations made and the action taken pursuant to such inspections. "This may be treated as top priority and compliance is required to be ensured strictly," the regulator said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfdV5a6
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drug

Alembic Pharmaceuticals has secured final approval from the USFDA for its generic Dasatinib tablets. These tablets are used to treat certain blood cancers in adults and children. The approval covers multiple strengths of the drug. Dasatinib is a vital medication for patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2v3le85
via IFTTT

Read More

Obesity drug Mounjaro becomes India's top-selling drug by value in October

Eli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps control blood sugar and slows digestion. Demand for such drugs is increasing in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MFQHWda
via IFTTT

Read More

'Opaque pricing cripples Ayushman drug coverage'

The Ayushman Bharat program successfully delivers hospital care, but it falters when tackling the high costs associated with medications for chronic and rare conditions. Patients frequently have to pay out of pocket for these essential drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUkz5Dv
via IFTTT

Read More

Apollo Hospitals eyes Q4 FY26 listing for HealthCo amid major restructuring

Apollo Hospitals plans to list its Apollo HealthCo arm by the fourth quarter of FY27, following a multi-layered restructuring. The hospital chain is also set to add approximately 3,650 operating beds over the next five years with an investment of Rs 8,300 crore, funded by internal accruals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aR9TDjW
via IFTTT

Read More

Bayer gets nod to market Kerendia for heart failure treatment

Bayer has secured approval in India for its therapy Kerendia to treat heart failure. This drug, finerenone, is already used for chronic kidney disease linked to type 2 diabetes. The expanded use targets heart failure types that have lacked effective treatments. Finerenone now addresses major health issues in India, including cardiovascular and kidney diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r75jNz8
via IFTTT

Read More

Sun Pharma’s US innovative drug sales surpass generics for the first time

Sun Pharma's U.S. innovative medicine sales have surpassed generics for the first time, driven by key products like Ilumya and Cequa. The launch of Leqselvi for alopecia has been well-received, with further growth anticipated from upcoming launches like Unloxcyt. This marks a significant shift in the company's revenue streams.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6reqMC
via IFTTT

Read More

Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences announced a significant development for beta-thalassemia patients. The US Food and Drug Administration has granted Orphan Drug Designation to Desidustat. This novel product aims to treat the rare blood disorder. The designation supports the development of medicines for diseases affecting fewer than 2 lakh people in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ixsU2Vp
via IFTTT

Read More

Sun Pharma's US innovative drug sales surpass generics for first time

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The company is evaluating its current footprint and considering localization options, though the tariff's impact on its product portfolio remains uncertain. Sun Pharma also confirmed upcoming launches and R&D investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7qIJbws
via IFTTT

Read More

Novelis says September fire at New York plant to hit FY26 cash flow up to $550-650 mn

Novelis anticipates a significant financial hit from a September fire at its New York plant. The company expects free cash flow to decrease by $550-650 million this financial year. Adjusted earnings before interest, tax, depreciation and amortisation will also be impacted. Restoration efforts are underway, with the Hot Mill expected to restart by end-December 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ios8Z9F
via IFTTT

Read More

Novelis expects cash flow impact of up to $650 mn from Oswego fire

Novelis anticipates a $550-$650 million negative impact on free cash flows this fiscal due to a September fire at its Oswego unit. The company expects to restart the hot mill in December, with insurance expected to cover 70-80% of property damage and business interruption losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iswVXtx
via IFTTT

Read More

Knee implant ceiling rates to be reviewed

Next week, the National Pharmaceutical Pricing Authority (NPPA) of India will delve into the pricing caps for knee implants, a move that previously helped slash costs for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OrTcBNL
via IFTTT

Read More

Glenmark to launch generic drug to treat metabolic acidosis in US

Glenmark Pharmaceuticals is set to launch an 8.4 per cent Sodium Bicarbonate Injection in the United States. This generic medication treats high acid levels in the body. The company expects to begin distribution this month. The drug is therapeutically equivalent to Abbott Laboratories' product. This move follows significant annual sales for the medication in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/niSgEa2
via IFTTT

Read More

Novo sharpens India focus with bigger bets on niche hospitals

Novo Holdings is boosting its investments in India. The company is looking at single-specialty hospitals and contract drugmakers. This move targets high-growth healthcare segments. Novo Holdings is already in talks with several Indian companies. Their investment size in India has grown significantly. They are focused on specialized healthcare and complex drug manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d7owOcB
via IFTTT

Read More

Cipla to fully acquire Inzpera Healthscience

Drug maker Cipla has acquired Inzpera Healthscience for approximately Rs 111 crore. This strategic move combines Inzpera's paediatric products with Cipla's distribution strength. The deal aims to boost growth and scalability in the pharmaceutical and wellness sector. Inzpera, founded in 2016, focuses on differentiated paediatric offerings. The acquisition marks a significant step for Cipla in expanding its market presence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsfdvb
via IFTTT

Read More

AIMS hospital founder looks to buy back PE investors' 49% stake

In a bold move to regain control, Narendra Pandey, the visionary behind the Asian Institute of Medical Sciences, is negotiating to repurchase a 49% share from private equity players. He aims to secure around ₹500 crore for this venture as the hospital’s current valuation hovers between ₹1,000-₹1,200 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJLiBpe
via IFTTT

Read More

AI helping doctors spend more time with patients, cut down on paperwork: Stanford Medicine’s Priya Singh

In an interview with The Economic Times, Priya Singh, Chief Strategy Officer and Senior Associate Dean at Stanford Medicine, talks about how Stanford is building the next generation of healthcare leaders through executive education and artificial intelligence. She explains that the programmes—targeted at senior and mid-level healthcare professionals—focus on leadership and innovation rather than serving as pathways to U.S. jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MCt83oO
via IFTTT

Read More